In this case study, a translational quantitative systems pharmacology (QSP) model is proposed for CD3 bispecific molecules capable of predicting trimolecular complex (trimer) concentration between drug, T-cell and tumor cell, and linking it to tumor cell killing.
The model was used to:
- Predict clinical starting dose of a P-cadherin/ CD3 bispecific construct (Pcad-LP-DART) using a MABEL approach
- Characterize the in vivo PK/PD relationship of Pcad-LP-DART across mouse xenograft efficacy models
- Translate from mouse to human for Pcad-LP-DART for prediction of clinical efficacy and to determine sensitive parameters impacting efficacy
The model can also be applied at early stages to aid in the design of CD3 bispecifics and to select molecules with optimal properties.
This webinar is ideal for scientists and decision makers in drug R&D who want to learn more about how to leverage QSP approaches to provide quantitative guidance for their drug discovery and development.